SCHEMBL6942011

SCHEMBL6942011

Clc1ccc(CC2CC3CCC(C2)N3)cc1

nearest known ligand 0.51

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.51
SLC6A4 P31645 4/20 0.50
SLC6A2 P23975 2/20 0.50
SLC6A3 Q01959 2/20 0.50
ALDH1A1 P00352 1/20 0.45
AVPR1A P37288 1/20 0.39
FPR2 P25090 1/20 0.37
PROKR1 Q8TCW9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5452433 0.82 SLC6A4 (0.47) KCNH2SLC6A4SLC6A2SLC6A3
SCHEMBL5452431 0.82 SLC6A4 (0.47) KCNH2SLC6A4SLC6A2SLC6A3
SCHEMBL7001856 0.81 SLC6A2 (0.46) SLC6A4SLC6A2SLC6A3
SCHEMBL4577960 0.81 GBA1 (0.55) SLC6A4SLC6A2SLC6A3
SCHEMBL13803916 0.81 GBA1 (0.55) SLC6A4SLC6A2SLC6A3
SCHEMBL13803960 0.81 GBA1 (0.55) SLC6A4SLC6A2SLC6A3
SCHEMBL13791895 0.81 GBA1 (0.55) SLC6A4SLC6A2SLC6A3
SCHEMBL12076803 0.81 GBA1 (0.55) SLC6A4SLC6A2SLC6A3
SCHEMBL5870737 0.81 PRMT5 (0.43) KCNH2SLC6A4SLC6A2SLC6A3FPR2
Hydrochloric Acid SCHEMBL3884381 0.80 CHRM1 (0.45) SLC6A4SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244450-A4 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-03-19 EP disclosed
EP-1244450-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-02 EP disclosed
US-6432976-B1 ANALGESICS; SIDE EFFECT REDUCTION MERCK & CO., INC. 2002-08-13 US disclosed
WO-2001032179-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO disclosed